Clinical Trial Update: CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports that CFI-402257, a potent and selective TTK inhibitor, is being studied in Phase 1/Phase 2 trials for advanced solid tumors a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• CFI-402257

Snippet

Sponsor: Treadwell Therapeutics, Inc | Conditions: Advanced Solid Tumor, Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING